What Do Pathologists Look For to Confirm Breast Cancer?

The earlier blogs on breast cancer have covered the basics of investigation and diagnosis. Now, we will explore in greater depth how pathologists dedicate their minds, hearts, and souls to ensuring the accuracy of their results, which ultimately helps clinicians make informed decisions.

Breast cancer is one of the most common cancers affecting women in India, and at the heart of every diagnosis is the pathologist — a specialist whose work, though largely unseen by patients, directly shapes the care they receive.  

Pathology in India faces unique challenges, including late detection and limited resources. Many women present with advanced disease due to a lack of awareness or access to screening. Pathologists bridge these gaps through careful tissue evaluation, ensuring that only those who truly need aggressive treatment receive it. Their input influences not just diagnosis, but also the selection of cost-effective therapies suited to India’s population-specific cancer conditions.

The role of a Pathologist

Pathologists hold a key position in breast cancer diagnosis. From the first biopsy to the final surgical specimen, they examine tissue under the microscope to confirm malignancy, distinguish invasive disease from in-situ, classify tumour type, and grade its aggressiveness based on cell appearance and division rate. 

Their involvement does not end at diagnosis: as treatment progresses, they re-examine surgical specimens, assess margin clearance, evaluate tumour response to chemotherapy, and contribute their findings to the Multidisciplinary Tumour Board, translating every test conducted into decisions at every point of an individual’s diagnostic pathway.

When metastatic disease is detected, pathologists act without delay — issuing preliminary findings to the oncologist, re-profiling the tumour for any shift in receptor status, and flagging the case for immediate MDT discussion. In urgent situations, they contact the treating team directly rather than wait for a scheduled review. When findings are uncertain, they do not guess: they seek a specialist second opinion, request a repeat biopsy if the sample is inadequate, or order additional molecular tests until a definitive answer is reached. Accuracy is never traded for speed. Routine biopsy results are typically available within three to five working days; complex cases requiring additional staining or molecular profiling may take up to two weeks. Reputable cancer centres in major Indian cities generally deliver comprehensive reports within five to seven days.

What Pathologists Examine

Sample Preparation Basics 

The process begins with fixing biopsy tissue in formalin, which preserves its structure for microscopic examination. Slicing the tissue into thin sections allows pathologists to observe the arrangement of ducts, lobules, and stroma. Routine stains, such as hematoxylin and eosin (H&E), highlight key features. Differences in tissue density, which are common among Indian women, can sometimes make interpretation more challenging, requiring extra attention to subtle abnormalities.

Key Cellular Clues 

Beyond overall architecture, pathologists focus on cellular details. Cancer cells often lose their uniform shape and size, with darkly stained nuclei and frequent mitoses, a sign of rapid growth. In India, certain subtypes like invasive ductal carcinoma are more prevalent. Recognising these distinctions is crucial, as it shapes further testing and treatment plans.

Invasion and Spread Signs 

Detecting invasion, where cancer cells breach normal boundaries, is a turning point in diagnosis. Pathologists look for cancer cells infiltrating fat or lymphatic spaces, which indicate a higher chance of spread. This information is especially vital in India, where aggressive types like triple-negative breast cancer are common and require prompt intervention.

Grading for Treatment Fit

Tumour grade provides insight into how aggressive the cancer is likely to be. Pathologists score tumours based on gland formation, nuclear features, and mitotic rate. In the Indian setting, where financial constraints are significant, accurate grading helps avoid overuse of expensive therapies and steers patients toward affordable, effective options like hormone therapy when appropriate.

Biomarker Checks 

Testing for biomarkers such as estrogen, progesterone, and HER2 receptors is standard. These tests determine eligibility for drugs like tamoxifen or Herceptin. Since such medications can be costly, knowing biomarker status helps avoid unnecessary expenses and enables more precise, tailored treatment, which is especially important in resource-limited settings.

Why It Matters Here 

Pathology reduces overtreatment and anxiety by confirming benign diagnoses in most breast lumps seen in India. Fast, accurate reports from trusted institutions or from efficient cancer testing laboratories such as Karkinos Healthcare provide women and their families with reassurance and guidance on next steps.

Blood tests are often an early step, though they cannot confirm breast cancer on their own. A complete blood count checks for anaemia or signs of infection, while liver and kidney function tests assess organ health — particularly if metastasis is suspected. Tumour markers such as CA 15-3 and CEA may be used to monitor treatment response or watch for recurrence, but are not used for initial diagnosis.

Tissue biopsy remains the gold standard. When examining a sample, pathologists assess whether the cells are benign or malignant, whether the cancer is confined (in situ) or has begun to invade surrounding tissue, and whether cancer cells are present at the edges of removed tissue, known as surgical margins.

Grading: How Aggressive Does the Tumour Look?

Grading describes how the cancer cells look compared to normal breast cells. Indian pathologists use the Nottingham Grading System (also called the Modified Scarff-Bloom-Richardson or Elston-Ellis system) — the same global standard recommended by the Indian Council of Medical Research (ICMR) and the Indian College of Pathologists.

Three features are assessed under the microscope, each scored from 1 to 3:

The three scores are added together to determine the final grade:

Each of the three features is scored from 1 to 3, giving a combined total between 3 and 9. A total of 3 to 5 is Grade 1 — the tumour cells still look relatively organised and are slow-growing. A total of 6 or 7 is Grade 2, indicating intermediate behaviour. A total of 8 or 9 is Grade 3 — the cells look markedly abnormal, divide rapidly, and are considered aggressive. The higher the score, the further the tumour has drifted from normal breast tissue.

• Grade 1 (Score 3–5): Well-differentiated, slow-growing
• Grade 2 (Score 6–7): Moderately differentiated, intermediate behaviour
• Grade 3 (Score 8–9): Poorly differentiated, aggressive and fast-growing

A typical Indian pathology report will present this information clearly — for example: Histologic Grade II; Tubule Formation Score 2; Nuclear Pleomorphism Score 2; Mitotic Count Score 2; Total Score 6/9.

The Ki-67 Index: The Tumour’s Speedometer

While the Nottingham grade describes how cancer cells look, the Ki-67 index measures how fast the tumour is actually growing. Ki-67 is a protein present only in cells that are actively preparing to divide. When a tissue sample is stained for Ki-67, dividing cells turn brown while resting cells stay blue. The index is simply the percentage of cancer cells that stain brown.

• Low Ki-67 (below ~10–15%): Few cells dividing — slow-growing tumour
• Intermediate Ki-67 (15–30%): Moderate growth — further testing may be considered
• High Ki-67 (above ~30%): Many cells dividing — aggressive tumour, chemotherapy usually recommended

Ki-67 also helps identify the subtype of hormone-positive (ER+) breast cancers: a low Ki-67 suggests Luminal A disease (slow-growing, good prognosis), while a high Ki-67 suggests Luminal B disease (faster-growing, often requiring more intensive treatment). For advanced-stage disease, receptor status (ER/PR/HER2) and PD-L1 levels tend to be the more critical values to track.

Staging: How Far Has the Cancer Spread?

Staging describes the extent of cancer in the body, using the universal TNM system:

• T (Tumour): Size and local extent of the primary tumour
• N (Nodes): Number and location of lymph nodes involved
• M (Metastasis): Whether cancer has spread to distant organs such as lungs, liver, bone or brain

Based on the TNM staging, breast cancer is grouped into stages from 0 to IV:

Stage 0: Also known as “in situ” cancer. The abnormal cells are confined to the ducts or lobules and have not invaded nearby tissue.

Stage I: Early-stage cancer where the tumour is small and may not have spread to lymph nodes, or only minimally.

Stage II: The tumour may be larger or has spread to a few nearby lymph nodes, but is still considered potentially curable.

Stage III: More advanced locally. The cancer may be larger, involve multiple lymph nodes, or extend to nearby tissues.

Stage IV: Also called metastatic breast cancer. The cancer has spread to distant organs such as bones, liver, lungs, or brain. 

Oncologists use the stage grouping to decide between surgery, chemotherapy, radiation, hormone therapy, and newer targeted treatments. The earlier the stage, the more localised the cancer and the better the chance of successful treatment,  while later stages still benefit from modern therapies that can prolong and improve life.

Staging is determined after surgery. Together with grade and molecular markers, it gives oncologists a complete picture of how the cancer is likely to behave and how aggressively it needs to be treated.

Trust in process

Receiving a pathology report can feel like being handed a document in a foreign language. But bear in mind that it is not a verdict; it lays the foundation for a specific treatment plan. 

Every number recorded on that page was analysed by a pathologist to give your oncologist precise, evidence-based ground to stand on. The waiting period between biopsy and report, and between report and treatment plan, is not inaction. It is the system working as it should.

A pathologist has been present at every stage of that process, from the biopsy that confirmed your diagnosis to the receptor testing that determined which therapies apply, to any re-profiling that may be needed if the disease evolves. That expertise is working in your favour before you ever walk into your oncologist’s room. Trust the process, trust the people behind it, and let science lead the way for the best treatment outcomes.

Medical disclaimer: This article is for general educational purposes only and does not constitute medical advice. Guidelines vary by centre, patient profile, and resource availability. Always consult a qualified oncologist or breast cancer specialist for individual guidance.